Business
Oncolytics Biotech® Announces First Patient Treated in MUK eleven Study
Oncolytics Biotech® Announces First Patient Treated in MUK eleven Study Canad...
About this update from Oncolytics Biotech Inc.
[{"type":"text","content":"\n\n\n\nOncolytics Biotech® Announces First Patient Treated in MUK eleven Study\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nCALGARY and SAN DIEGO, Sept. 14, 2017\n\n\n\nCALGARY and SAN DIEGO, Sept. 14, 2017 /CNW/ - Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX: ONCYF) (Oncolytics or the Company), a biotech company developing REOLYSIN® (pelareorep), a first-in-class, systemically delivered immuno-oncolytic virus that activates the innate and adaptive immune systems, today announced that the first patient has been treated in the Phase 1b trial MUK eleven, studying REOLYSIN in combination with Celgene Corporation's immunomodulatory drugs (IMiDs), Revlimid® or Imnovid® as a rescue treatment in relapsing myeloma patients.\n\n\"This is an important trial for Oncolytics as it's the first to discretely examine the innate immunity component of REOLYSIN's mechanism of action,\" said Dr. Matt Coffey, President and CEO of Oncolytics Biotech. \"MUK eleven and REO 024, our trial evaluating the induction of an inflamed tumor phenotype of REOLYSIN  in a combination with Keytruda, collectively demonstrate our strategy to assess the safety and efficacy of REOLYSIN in combination with immunomodulatory and immuno-oncology drugs, the impact of these combinations on the immune system and to explore new clinical applications.\"\n\n\"We are pleased to have enrolled the first patient in MUK eleven, a trial focused on a novel area of myeloma research,\" said Dr. Simon Ridley, Director of Research at Myeloma UK. \"Our Clinical Trial Network is focused on strategic, collaborative and innovative approaches to delivering trials and treatments to patients and this pioneering trial has the potential to offer a novel future treatment strategy in myeloma.\"\n\nMUK eleven is a first-of-its-kind immunotherapy trial that aims to modulate the immune system to target myeloma. The trial, run through the Myeloma UK Clinical Trial Network (CTN) in collaboration with charity Myeloma UK, the University of Leeds and Celgene, launched in March of this year and will r...